IngredientsSynsepalum dulcificum is an evergreen shrub belonging to the Sapotaceae family, Synsepalum genus. It is a plant native to tropical Africa, known for its berry that, when eaten, causes sour foods such as lemons and limes subsequently consumed to taste sweet. Common names for this species and its berry include miracle fruit, miracle berry, miraculous berry, sweet berry, and in West Africa, where the species originates, àgbáyun (in Yoruba), taami, asaa, and ledidi.
The miracle fruit plant is also referred to in the scientific literature as Richardella dulcifica (Schumach. & Thonn.) Daniell, an accepted synonym. Additional historical synonyms recorded in the taxonomic literature include Bakeriella dulcifica, Bumelia dulcifica, Pouteria dulcifica, and Sideroxylon dulcificum.
The miracle fruit plant grows as a dense shrub or small tree, usually not more than 5.5 meters (18 feet) in height in the wild and generally smaller when cultivated. The simple leaves are oval and tapering at the base with smooth margins and feature a waxy underside; they grow in spirelike clusters at the ends of small branches. The small white flowers give rise to red drupe fruits that are about 2–3 cm (0.8–1.2 inches) in length. Plants typically begin producing fruit after three or four years and require acidic soil.
Miracle berry has a large seed surrounded by a thin layer of berry flesh with a faint cherry-like flavor. The pulp of the fruit is the only part of the fruit that contains miraculin, and it comprises just 4.44% of the weight of the fresh fruit. The berry itself has a low sugar content and a mildly sweet tang.
Synsepalum dulcificum is indigenous to West and Central Africa, including the countries of Congo, Nigeria, and Ghana. It is currently cultivated in Taiwan, China, the USA, Ecuador, Colombia, and Puerto Rico.
The Synsepalum dulcificum fruit has a history of use in West Africa and in several countries of other regions as a fresh fruit, pulp, puree, and other types of preparation. In contemporary markets, the fruit is processed into several commercially relevant forms:
The names "miracle fruit" and "miracle berry" are also shared by Gymnema sylvestre and Thaumatococcus daniellii, which are two other species used to alter the perceived sweetness of foods, and care should be taken to distinguish these botanically unrelated plants.
The taste-modifying property of miracle fruit has been known for centuries to the people of tropical Western and Central Africa, who also employ different parts of the plant in the management of various ailments.
Europeans learned of the fruit at least in the 18th century, when the French explorer Chevalier des Marchais provided an account of its use: during a 1725 excursion to West Africa, he noticed that local people picked the berry from shrubs and chewed it before meals. Chevalier des Marchais described the fruit of a shrub that had the property to soften what is acidic, and noted the fruit was cultivated by natives of Nigeria and Benin. The first thorough botanical description was written by British surgeon F.W. Daniell in 1852, who noted that West Africans consumed it before eating a number of acidic native foods.
There has been a growing interest in the potential use of the plant for centuries by local people of West Africa, where the fruit has been used to sweeten sour foods and beverages such as Koko and Kenkey made from fermented maize and millet, and palm wine. The miracle fruit plant is native to tropical West Africa, where it is used locally to sweeten palm wine and other beverages.
The berry has been used in West Africa for a long time and is a part of the diet of the Yoruba people. In traditional medicine across the plant's range, the leaves are the most useful plant parts (accounting for 90% of ethnomedicinal uses), followed by the root (7%), bark (1.5%), stem (1%), and fruit (0.5%). Information on ethnomedicinal uses documented in the scientific literature was obtained from sources spanning seven countries, with the highest number of uses recorded in West Africa. The literature shows a high degree of consensus for at least two major categories of diseases for which this plant is used: diabetes and sexually-related diseases.
In some African countries, all parts of the miracle fruit plant — but particularly its leaves — play an essential role in traditional medicine. In Benin, the leaves are used to treat diabetes, hyperthermia, and enuresis (bedwetting).
In the 1980s in the United States, an attempt was made to commercialize the fruit for its ability to mask non-sweet foods as sweet without a caloric cost, but the Food and Drug Administration classified the berry as a food additive and required evidence of safety.
The flavor-altering mechanism of miracle fruit is due to a glycoprotein named miraculin, which was first isolated by Japanese researcher Kenzo Kurihara in 1968. Miraculin was sequenced in 1989 by Japanese scientists, establishing it as the taste-modifying protein that gives the miracle fruit its defining property.
The sweetening property of miracle fruit is due to miraculin, a glycoprotein consisting of 191 amino acids and some carbohydrate chains, found in the pulp of the berry. Miraculin is a single polypeptide chain having a molecular weight of 24,600 kDa with two sugars linked to two amino acid residues. The dried novel food form of the berry contains miraculin at a concentration of ≤2.5%.
Miracle fruit has been reported to contain potent antioxidative phytochemicals including epicatechin, rutin, quercetin, myricetin, kaempferol, gallic acid, ferulic acid, syringic acid, delphinidin glucoside, cyanidin galactoside, and malvidin galactoside, as well as α-tocotrienol, α- and γ-tocopherol, and lutein.
The bright red colour of the fruit is indicative of the presence of beneficial antioxidant flavonoids, especially anthocyanins. The whole fruit, comprising the skin, pulp, and seed, was found to contain the highest concentrations of ascorbic acid and all the identified phenolic compounds, except for caffeic acid, carnosic acid, cinnamic acid, and myricetin, which were more concentrated in the pulp matrices.
Research has shown that miracle fruit contains a large amount of vitamin C (40.1 mg/100 g fresh fruit weight), a high phenolic content (625.57 mg GAE/100 g FW), and high antioxidant capacity (457.3 μmol Trolox/100 g FW), with low total sugar content.
Among the essential amino acids present in the berry pulp, leucine (2.35 g/100 g protein) is the highest while methionine (0.31 g/100 g protein) is the lowest. Glutamic acid (3.43 g/100 g protein) is the most abundant non-essential amino acid. Analysis of oxidizable vitamins reveals that vitamin C (1.33 mg/100 g) is more abundant than vitamin A (2.54 µg) and vitamin E (0.78 mg/100 g).
Apart from miraculin, other pharmacologically active compounds identified in the plant include alkaloids (dihydro-feruloyl-5-methoxytyramine, N-cis-caffeoyltyramine, N-cis-feruloyl-tyramine), lignans (syringaresinol, epi-syringaresinol), phytosterols, and triterpenoids. The plant is also endowed with various classes of phytochemicals, including flavonoids, tannins, alkaloids, and saponins.
In a phytochemical investigation of the leaves, seventeen compounds were isolated and identified from an ethyl acetate extract, all of which were obtained from S. dulcificum for the first time. Compounds 6, 7, 13, and 14 of the isolates exhibited significant antioxidant activity in DPPH and ABTS+ assays, suggesting potential application as antioxidant agents.
Miraculin is a glycosylated protein that acts on the human sweet taste receptor of the tongue (hT1R2, hT1R3). It binds only in acidic conditions, which allows conversion of sour stimuli to sweet. The effects last 1 to 2 hours, although the intensity declines with time.
According to early research, the miracle fruit effect occurs when miraculin is bound to taste cell membranes near the sweet receptor site. The receptor membrane undergoes a structural change in the presence of protons (H+), causing the sugar part of the miraculin molecule to bind to the sweet receptor site in the membrane, thereby evoking a strong sensation of sweetness. The basis of the sweetness-inducing behavior under acidic conditions is thus the pH-dependent conformational changes of the receptor membrane that detects the sweet sensation.
This effect lasts until the miraculin is diluted and eliminated by saliva. Miraculin itself has no taste, but stimulates a sweet taste estimated to be 400,000 times sweeter than sucrose on a molar basis.
At a neutral pH, miraculin itself does not taste sweet. When taste buds are exposed to miraculin, the protein binds to the sweetness receptors, and this causes normally sour-tasting acidic foods, such as citrus, to be perceived as sweet.
The antioxidant activity of miracle berry flesh and seed extracts has been evaluated using free radical scavenging methods including ABTS, DPPH, and FRAP. Miracle fruit powder (MFP) contains higher total phenolic compounds, flavonoids, and anthocyanins than the water extract, and consequently exerts greater DPPH and ABTS radical scavenging activity and reducing power.
Miraculin and other phytochemicals found in the plant, such as flavonoids and saponins, may be responsible for observed hypoglycemic outcomes. α-amylase and α-glucosidase inhibitory actions have also been observed in S. dulcificum fruit and leaf extracts.
Evaluated miracle fruit extracts — including water, butanol, ethyl acetate (EA), and hexane fractions — exerted potential for reduction of uric acid and inhibited xanthine oxidase activity in vitro and in monosodium urate (MSU)-treated RAW264.7 macrophages. The butanol extracts of miracle fruit attenuated oxonic acid potassium salt-induced hyperuricaemia in ICR mice by lowering serum uric acid levels.
The taste-modifying effect of miraculin on human sensory perception is the most robustly demonstrated property of the fruit and is supported by both mechanistic and clinical data.
Miraculin, a naturally occurring protein in miracle fruit, has the unusual ability to transduce a sweet signal in an acidic environment, profoundly changing food taste profiles for a short duration, masking unpleasant tastes, and increasing the palatability of certain foods. A pilot study was designed to determine whether consumption of the Miracle Fruit supplement would improve chemotherapy-associated taste changes, thereby improving the taste of food and ultimately leading to better nutrition.
A pilot clinical trial involving 23 patients with dysgeusia derived from chemotherapy treatment demonstrated that the consumption of this berry was safe, and 30% of patients showed an improvement in taste after two weeks of treatment. Another pilot trial conducted two years later on eight patients who experienced taste disturbances after chemotherapy treatment showed that all patients demonstrated improvements in taste, with five patients reporting the disappearance of the metallic taste after supplementation with the fruit.
An analysis of 9 total clinical studies highlights the potential of S. dulcificum consumption in aiding oncologic care, as evidenced by its effects on improving sweet taste perception, increasing caloric intake, altering oral/intestinal microbiota, and improving musculoskeletal and dermatologic health. Larger cohorts, intervention standardization, and further trials will be needed to further support translation of miracle berry into oncologic care.
Preliminary data suggest Synsepalum dulcificum may change taste sensation from sour to sweet in patients undergoing chemotherapy, but it has not been shown to prevent weight loss. Miracle fruit has been proposed for use in taste changes caused by chemotherapy and for weight loss, but studies are quite limited.
Despite the absence of substantial clinical evidence, prior uncontrolled pilot studies have hinted at the potential of using miracle fruit as a natural dietary supplement, presenting a promising nutritional strategy for managing dysgeusia.
Evidence strength: Preliminary. The available human studies are small (n = 8 to 23), largely uncontrolled or pilot in design, and confirmatory randomized controlled trials with adequate sample sizes remain ongoing.
Miracle fruit has been investigated as a potential tool for reducing caloric intake by making low-calorie or unsweetened foods more palatable.
Although miracle fruit may make things taste sweeter, it has not been shown to help weight loss. Miracle fruit has been proposed for use in weight loss, but studies are quite limited, and data suggest that some patients undergoing chemotherapy reported improved taste but no change in weight with miracle fruit.
Evidence strength: Insufficient. The theoretical rationale (substituting sour, low-sugar foods for calorie-dense sweet foods) is plausible, but no controlled trials have demonstrated a weight loss benefit.
The effect of miracle fruit on insulin sensitivity was considerable after treatment with miracle fruit powder. S. dulcificum fruit (50% and 100%) and leaf (50% and 100%) extracts had significant hypoglycemic effects on blood glucose levels in animal models.
Dulcificum fruit and leaf extracts showed significant α-amylase and α-glucosidase inhibitory activities, and molecular docking analyses suggested that some polyphenolic components of the plant possess strong binding to relevant enzymes, consistent with an antidiabetic mechanism.
The plant has a longstanding history as a folk remedy for diabetes, and these findings establish a foundation for the future application of S. dulcificum in the prevention and treatment of diabetes.
Evidence strength: Primarily preclinical (animal models and in vitro). Human clinical trials specifically designed to evaluate the antidiabetic effects of S. dulcificum directly are limited. A registered clinical trial (NCT05468411) is examining the acceptability of miracle fruit and its effect on energy intake among diabetic patients, comparing oral application of miracle fruit pill with a placebo on the likings of different sour food products and energy intake from meals in people with diabetes or prediabetes.
Gout is an inflammatory disease caused by the over-production of uric acid in the blood and crystallization of monosodium urate (MSU) in tissues. This process is driven by neutrophil influx into joints, leading to acute inflammatory arthritis with severe pain.
Miracle fruit extracts exerted potential for reduction of uric acid and inhibited xanthine oxidase activity in vitro and in MSU-treated RAW264.7 macrophages. Butanol extracts attenuated oxonic acid potassium salt-induced hyperuricaemia in ICR mice by lowering serum uric acid levels. These effects were equal to those of allopurinol, suggesting that the butanol extract of miracle fruit could be developed as a novel anti-hyperuricaemia agent or health food.
Evidence strength: Preclinical only (in vitro and mouse models). No human clinical trials on this application have been published.
In vitro, miracle fruit has been shown to inhibit malignant cell proliferation. Two chemicals present in S. dulcificum, syringaresinol and epi-syringaresinol, exhibit inhibitory effects on human skin cancer cells and considerable antioxidant activity in vitro.
Other beneficial characteristics of the fruit include antioxidant and anticancer abilities attributable to the various amides present in miracle fruit.
Flavonoids including anthocyanins have been reported as anticancer and chemopreventive agents and as potential functional ingredients.
Evidence strength: Preclinical only (cell lines and animal models). The clinical relevance of these in vitro findings has not been established in human studies. The use of miracle berry in oncology to date has focused on managing chemotherapy-induced dysgeusia rather than on direct antitumor effects.
Preclinical experiments found antioxidant, antihyperglycemic, and cholesterol-lowering effects. The antioxidant activity of miracle berry extracts has been thoroughly characterized in laboratory settings. Epicatechin, rutin, quercetin, myricetin, kaempferol, gallic acid, ferulic acid, syringic acid, three anthocyanins, three tocopherols, and lutein were identified and quantified in the miracle berry flesh. Some of the important antioxidant-rich phenolics and ascorbic acid in the miracle berry were found at much higher levels than in well-recognised antioxidant-rich berries such as blueberry.
Evidence strength: In vitro and preliminary. These in vitro findings demonstrate a capacity for free radical scavenging but have not been translated into confirmed clinical outcomes in humans.
Reviews of the scientific literature have identified S. dulcificum as a potent medicinal plant associated with antioxidant, antidiabetic, antimicrobial, anticancer, anti-hyperuricemic, hepatoprotective, anti-hyperlipidaemic, and anticonvulsant activities, with low toxicity shown. Cholesterol-lowering effects have been described in preclinical studies, including a 2020 study published in the Journal of Food Biochemistry examining the cholesterol-lowering activity of S. dulcificum.
Evidence strength: Preclinical only. No human clinical trials have demonstrated lipid-lowering benefits.
Scientific investigations have unravelled several pharmacological properties of the plant, which include antidiabetic, blood cholesterol-lowering, anti-hyperuricaemia, antioxidant, anticonvulsant, and anticancer properties. Anticonvulsant activity has been reported in animal studies, but no human clinical data are available.
Evidence strength: Preclinical only.
Researchers have conducted numerous studies on this herb, but there is a lack of an appropriate standardized dosage and safety evaluation for usage in therapeutic purposes.
The following dosages are reported directly from published sources and regulatory evaluations:
No standardized therapeutic dosage has been established for any clinical indication, and the above values are reported from specific study or regulatory contexts only.
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) delivered an opinion on dried fruits of Synsepalum dulcificum as a novel food pursuant to Regulation (EU) 2015/2283. The provided genotoxicity studies do not raise concerns for genotoxicity of the novel food. The Panel concludes that the only dose tested in a 90-day oral toxicity study — 2,000 mg/kg body weight per day — was not associated with adverse effects.
The EFSA approved miracle berry as a novel food pursuant to Regulation (EU) 2015/2283.
In the 1980s in the United States, an attempt was made to commercialize the fruit for its ability to mask non-sweet foods as sweet without a caloric cost, but the Food and Drug Administration classified the berry as a food additive and required evidence of safety. Miraculin, as an isolated protein, still does not have formal Generally Recognized As Safe (GRAS) status from the FDA for use as a food additive. Despite commercial food limitations, freeze-dried berries and tablets are legally available for purchase and use as dietary supplements.
In a preliminary analysis of a pilot study conducted in patients undergoing chemotherapy, the Miracle Fruit was found to be safe for use in patients undergoing chemotherapy, and the response to the fruit appeared encouraging.
There is currently little information on possible interactions between Synsepalum dulcificum and medications. Due to its influence on glucose metabolism and regulating lipid concentration, patients on antidiabetic or lipid-lowering medications should exercise caution.
The novel food form (dried pitted fruit) is intended to be used as a food supplement for the general population, excluding pregnant and lactating women and children.
Fresh miracle fruits are highly perishable and cannot be cooked because the taste-modifying effect found in the pulp of the miracle fruit is due to a protein (miraculin) that is deactivated by heat. This has practical implications for food processing and preparation, as thermal treatment destroys the active compound.
The FDA maintains that its classification of the miracle berry as a food additive was based on a lack of sufficient scientific data to support its safe consumption, arguing that the long-term effects of consuming miraculin were not adequately understood. Independent regulatory assessments (e.g., EFSA) have since generated genotoxicity and sub-chronic toxicity data supporting safety at proposed supplemental intakes, but comprehensive long-term human safety data remain limited.
There is a lack of an appropriate standardized dosage and safety evaluation for usage in therapeutic purposes, and ongoing research should be pursued in order to produce medicines for the treatment of a variety of disorders; miraculin metabolites may also serve as biomarkers for the identification of various disorders.
Future research on the changes in food preferences with the optimum miraculin dose, food type, and intrapersonal variations in taste sensitivity is warranted.
Future research may further explore the corresponding phytochemicals, associated molecular mechanisms, and the toxicological and pharmacokinetic profile before subjecting to broad clinical testing.
A Phase 3 randomized clinical trial (NCT05486260) is currently evaluating miraculin for taste dysfunction in head and neck cancer patients, with safety tests on miraculin suggesting it is well-tolerated in this context.
Health conditions that Magic fruit may help support.
Body systems that Magic fruit may help support.
Go back